Author

N. Cheedarla

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 3 Assay:proteomics· 3 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:mouse· 1

Frequent Co-Authors

A. Chandele· 2 shared A. Patel· 2 shared A. S. Neish· 2 shared A. Sahoo· 2 shared A. Sharma· 2 shared A. Shiferaw· 2 shared C. Chakravarthy· 2 shared C. W. Davis· 2 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Chandele

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response

A. Patel, S. Kumar, L. Lai, C. Chakravarthy, R. Valanparambil, E. S. Reddy, K. Gottimukkala, P. Bajpai, D. R. Raju, V. V. Edara, M. E. Davis-Gardner, S. Linderman, K. Dixit, P. Sharma, G. Mantus, , E. A. Ortlund

The paper identifies three monoclonal antibodies that poorly neutralize the Omicron BA.1 variant, revealing structural and molecular features of antibody evasion.

bioRxiv · Oct 24, 2022Immunology

Structural insights for neutralization of BA.1 and BA.2 Omicron variants by a broadly neutralizing SARS-CoV-2 antibody

S. Kumar, A. Patel, L. Lai, C. Chakravarthy, R. Valanparambil, M. E. Davis-Gardner, V. V. Edara, S. Linderman, E. S. Reddy, K. Gottimukkala, K. Nayak, P. Bajpai, V. Singh, F. Frank, N. Cheedarla, , A. Chandele

This paper identifies and structurally analyzes an antibody that neutralizes SARS-CoV-2 BA.1 and BA.2 variants, revealing its unique epitope and mechanism of action.

bioRxiv · May 13, 2022Immunology

Changes at V2 apex of HIV-1 Clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies

A. Sahoo, E. A. Hodge, C. LaBranche, T. T. Styles, X. Shen, N. Cheedarla, A. Shiferaw, G. Ozorowski, W.-H. Lee, A. B. Ward, G. D. Tomaras, D. C. Montefiori, D. J. Irvine, K. K. Lee, R. R. Amara

bioRxiv · Jun 15, 2021 · PreprintImmunology

Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response

N. K. Routhu, S. Gangadhara, N. Cheedarla, A. Shiferaw, S. A. Rahman, A. Sahoo, P.-Y. Shi, V. D. Menachery, K. Floyd, S. Fischinger, C. Atyeo, G. Alter, M. S. Suthar, R. R. Amara

This study develops two MVA-based SARS-CoV-2 vaccines, MVA/S and MVA/S1, and finds that MVA/S induces stronger neutralizing antibodies against SARS-CoV-2 compared to MVA/S1.

bioRxiv · Jun 27, 2020 · PreprintImmunology

Systemic inflammation and risk of age-associated diseases in people living with HIV on long term suppressive antiretroviral therapy

H. Babu, A. T. Ambikan, E. E. Gabriel, S. Svensson Akusjarvi, A. N. Palaniapan, V. Sundaraj, N. R. Muppani, M. Sperk, N. Cheedarla, R. Sridhar, S. P. Tripathy, P. Nowak, L. E. Hanna, U. Neogi

This study evaluates systemic inflammation and age-associated disease risk in HIV-positive individuals on long-term ART, finding persistent inflammation and telomere shortening despite viral suppression.

bioRxiv · May 24, 2019 · PreprintImmunology